SCHEMBL2714907

SCHEMBL2714907

Cc1cccnc1-c1nc2cc(F)cc(F)c2c(Cl)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 1/20 0.34
SQOR Q9Y6N5 1/20 0.34
DHODH Q02127 2/20 0.34
CYP2A6 P11509 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
SMO Q99835 3/20 0.33
ALDH1A1 P00352 1/20 0.33
CACNA1B Q00975 1/20 0.33
APBA1 Q02410 1/20 0.33
PIK3CA P42336 2/20 0.33
MET P08581 3/20 0.32
SRC P12931 2/20 0.32
KDR P35968 2/20 0.32
KIT P10721 1/20 0.32
FGFR2 P21802 1/20 0.32
AXL P30530 1/20 0.32
FLT3 P36888 1/20 0.32
MST1R Q04912 1/20 0.32
TGFBR1 P36897 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2713623 0.85 PDE10A (0.43) MAPK14DHODHPIK3CATGFBR1
SCHEMBL245592 0.82 KDM4E (0.49) KDM4ENPC1PIK3CAPIK3CD
SCHEMBL2711810 0.81 MBNL1 (0.37) MAPK14DHODHPIK3CA
SCHEMBL2710817 0.80 PDE1A (0.38) MAPK14SQORDHODHNPC1
SCHEMBL2713014 0.79 DHODH (0.42) DHODHCYP2A6KDM4E
SCHEMBL2710938 0.77 MBNL1 (0.48) DHODHPIK3CAPIK3CD
SCHEMBL2712520 0.77 MAPK14 (0.48) MAPK14DHODHKDM4EALDH1A1
SCHEMBL244823 0.77 PIK3CA (0.47) CYP2A6KDM4ENPC1PIK3CAPIK3CD
SCHEMBL2608573 0.77 MAPK14 (0.43) MAPK14PIK3CA
SCHEMBL249053 0.77 DHODH (0.37) MAPK14DHODHPIK3CAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
EP-2445886-B1 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS AMGEN INC (US) 2016-03-30 EP disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
US-8940724-B2 Quinoline derivitives and their uses AMGEN INC. (US) 2015-01-27 US disclosed
EP-2445886-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES Amgen, Inc (US) 2012-05-02 EP disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-30 US disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed
WO-2010151791-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES AMGEN INC. (US) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331293-A1 HETEROCYCLIC COMPOUNDS AND THEIR USES MCL1, MALT1, BCL9 MAPK14 705/4885SQOR 3584/4885DHODH 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.